Although we found survival benefits among all NEN types after receiving GLP-1Ra therapy in the present study, our findings contrast with select preclinical and clinical studies demonstrating tumor progression in GLP-1R-expressing pancreatic NENs treated with these agents [26,27]. This evidence concerns the gene GLP1R and neoplasm.